File download
Send files
Remove all

Admescope Blog

It's getting close to Midsummer

18 June 2019

The first half of 2019 is nearing its end and I can tell you that the time has truly flown by. The Sales and marketing team has been keeping busy flying and driving around Europe these past few months. We’ve visited seven different countries on roadshows, attended several conferences and as a result met a lot of new interesting people and old acquaintances.
Read more
Tags: , Admescope

ADME – how to get started?

29 May 2019

During preclinical drug development, the number of compounds decreases from hundreds or thousands to the one entering the clinical trials. Understanding the ADME properties is essential to guide the decision makers and hence, ADME studies constitute an important part of preclinical drug development. When initiating this line of work for the first time, it may appear a bit puzzling. So, let’s have a simplified overview how get started with small molecules.
Read more
Tags: , ADME, pre-clinical

Protein quantification with mass spectrometry

3 May 2019

The development of analytical techniques has enabled applying mass spectrometry methods also for protein quantification from biological samples. The use of LC/MS brings in more analytical potential due to its versatility and accuracy and hence, its importance as an analytical tool for protein characterisation is increasing. If not being familiar with the topic, it may be interesting to have a peek how proteins are quantified from biological matrixes with LC/MS.
Read more
Tags: , Biologics

In the cell lab

10 April 2019

A big portion of our in vitro ADME assays are performed using intact cells which have special requirements for assay conditions. To address these requirements these studies are performed in a separate lab dedicated to cell-based work. Why don’t we take a closer look at what goes on in our cell lab?
Read more

Metabolites in safety testing (MIST)

5 February 2019

After administration into a body, the drug is usually metabolised into metabolites, which may also be associated with toxic effects. This is why the MIST strategy has evolved to ensure that human metabolites have been adequately covered in the preclinical safety studies. Admescope site manager Sweden Dr Johanna Haglund will describe how to tackle this question.
Read more
Tags: , in vivo DMPK